Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 4 institutions in 1 country.
Sandip K BasuDepartment of Ophthalmology, The University of Health Science Centre, Memphis, TN 38163, USA.
Amanda PrislovskyDepartment of Ophthalmology, The University of Health Science Centre, Memphis, TN 38163, USA.
Nataliya LenchikDepartment of Ophthalmology, The University of Health Science Centre, Memphis, TN 38163, USA.
Daniel J StephensonDepartments of Medicine and Cell Biology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Rajesh AgarwalDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Charles E ChalfantDepartments of Medicine and Cell Biology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA.
Nawajes MandalDepartment of Ophthalmology, The University of Health Science Centre, Memphis, TN 38163, USA.ORCID 0000-0003-4489-7748
University of Tennessee Health Science Center · USUnited States Department of Veterans Affairs · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Virginia · US
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Tissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E. · 2013 to 2024
$19.9M
The roles of ceramide and its derivatives in A. phagocytophilum pathogenesisR01AI139072 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHARLES E. CHALFANT, Jason A Carlyon · 2018 to 2026
$5.7M
Sphingolipids and their Impact in Corneal Wound HealingR01EY031316 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI KARAMICHOS, DIMITRIOS, MANDAL, NAWAJES · 2020 to 2023
$1.8M
Sphingolipid Metabolism and Signaling in the RetinaR01EY022071 · NEI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MANDAL, NAWAJES · 2012 to 2016
$1.8M
The role of ceramide kinase in mitophagyR01GM137578 · NIGMS · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E. · 2020 to 2023
$1.3M
BLRD Research Career Scientist Award ApplicationIK6BX004603 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2019 to 2025
–
BCCMA: The Role of Sphingolipids in the Induction & Maintenance of Non-Small Cell Lung Cancer by Oncogenic KRASI01BX006063 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHARLES E. CHALFANT · 2024 to 2026
–
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunctionI01BX004893 · VA · MIAMI VA HEALTH CARE SYSTEM · PI GALOR, ANAT, MANDAL, NAWAJES · 2021 to 2025
–
The role of RNA splicing in non-small cell lung cancerI01BX001792 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI CHALFANT, CHARLES E. · 2013 to 2024
–
BLRD VA I01 BX001792BLRD VA I01 BX004893BLRD VA I01 BX006063BLRD VA IK6 BX004603NCI NIH HHS P01 CA171983NCI NIH HHS P30 CA044579NEI NIH HHS R01 EY022071NEI NIH HHS R01 EY031316NIAID NIH HHS R01 AI139072NIGMS NIH HHS R01 GM137578
6 · The paper itself
Abstract
Vesicating chemicals like sulfur mustard (SM) or nitrogen mustard (NM) can cause devastating damage to the eyes, skin, and lungs. Eyes, being the most sensitive, have complicated pathologies that can manifest immediately after exposure (acute) and last for years (chronic). No FDA-approved drug is available to be used as medical counter measures (MCMs) against such injuries. Understanding the pathological mechanisms in acute and chronic response of the eye is essential for developing effective MCMs. Here, we report the clinical and histopathological characterization of a mouse model of NM-induced ocular surface injury (entire surface) developed by treating the eye with 2% (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mouse Model of Nitrogen Mustard Ocular Surface Injury Characterization and Sphingolipid Signaling. · full record | OpenQuestion